Antitumor applications of stimulating Toll-like receptor 9 with CpG oligodeoxynucleotides

Current Oncology Reports

Volumn 6, Issue 2, 2004, Pages 88-95

  Krieg, Arthur M ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; ANTINEOPLASTIC AGENT; CANCER ANTIBODY; CANCER VACCINE; CPG OLIGODEOXYNUCLEOTIDE; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DINUCLEOTIDE; FREUND ADJUVANT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEPATITIS VACCINE; IMMUNOSTIMULATING AGENT; INTERLEUKIN 10 RECEPTOR ANTIBODY; LIGAND; MONOPHOSPHORYL LIPID; PROTEIN ANTIBODY; QS 21; RECOMBINANT CYTOKINE; TOLL LIKE RECEPTOR 9; TOPOTECAN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; CELL SURFACE RECEPTOR; CPG OLIGONUCLEOTIDE; CPG-OLIGONUCLEOTIDE; IMMUNOLOGICAL ADJUVANT; MEMBRANE PROTEIN; OLIGODEOXYRIBONUCLEOTIDE; TLR9 PROTEIN, HUMAN; TOLL LIKE RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; B LYMPHOCYTE ACTIVATION; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; DNA METHYLATION; DRUG POTENTIATION; DRUG RECEPTOR BINDING; HEPATITIS C; HUMAN; HUMORAL IMMUNITY; IMMUNOSTIMULATION; LUNG CANCER; LYMPHOCYTE TRANSFUSION; MELANOMA; NONHUMAN; PROKARYOTE; REVIEW; RHABDOMYOSARCOMA; SIDE EFFECT; UTERINE CERVIX CANCER; VIRUS GENOME; ANIMAL; ANIMAL MODEL; ARTICLE; CPG ISLAND; DRUG EFFECT; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; MOUSE; NEOPLASM;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CPG ISLANDS; HUMANS; IMMUNOTHERAPY; MEMBRANE GLYCOPROTEINS; MICE; MODELS, ANIMAL; NEOPLASMS; OLIGODEOXYRIBONUCLEOTIDES; RECEPTORS, CELL SURFACE; TOLL-LIKE RECEPTOR 9; TOLL-LIKE RECEPTORS;

EID: 2342558523     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-004-0019-0     Document Type: Review

References (71)

1. Takeda K, Kaisho T, Akira S: Toll-like receptors. Annu Rev Immunol 2003, 21:335-376.
2. Ahmad-Nejad P, Hacker H, Rutz M, et al.: Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur J Immunol 2002, 32:1958-1968.
3. Bauer S, Kirschning CJ, Hacker H, et al.: Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci U S A 2001, 98:9237-9242.
4. Krug A, Towarowski A, Britsch S, et al.: Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol 2001, 31:3026-3037.
5. Kadowaki N, Ho S, Antonenko S, et al.: Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med 2001, 194:863-870.
6. Hornung V, Rothenfusser S, Britsch S, et al.: Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 2002, 168:4531-4537.
7. Hartmann G, Weeratna RD, Ballas ZK, et al.: Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J Immunol 2000, 164:1617-1624.
8. Krieg AM: CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002, 20:709-760.
9. Krug A, Rothenfusser S, Hornung V, et al.: Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J Immunol 2001, 31:2154-2163.
10. Krieg AM, Yi AK, Matson S, et al.: CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995, 374:546-549.
11. Sparwasser T, Vabulas RM, Villmow B, et al.: Bacterial CpG-DNA activates dendritic cells in vivo: T helper cell-independent cytotoxic T cell responses to soluble proteins. Eur J Immunol 2000, 30:3591-3597.
12. Kobayashi H, Horner AA, Takabayashi K, et al.: Immunostimulatory DNA pre-priming: a novel approach for prolonged Th1- biased immunity. Cell Immunol 1999, 198:69-75.
13. Lipford GB, Sparwasser T, Zimmermann S, et al.: CpG-DNA-mediated transient lymphadenopathy is associated with a state of Th1 predisposition to antigen-driven responses. J Immunol 2000, 165:1228-1235.
14. Blackwell SE, Krieg AM: CpG-A-induced monocyte IFN-gamma-inducible protein-10 production is regulated by plasmacytoid dendritic cell-derived IFN-alpha. J Immunol 2003, 170:4061-4068.
15. Hartmann G, Weiner GJ, Krieg AM: CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. Proc Natl Acad Sci U S A 1999, 96:9305-9310.
16. Kadowaki N, Antonenko S, Liu YJ: Distinct CpG DNA and polyinosinic-polycytidylic acid double-stranded RNA, respectively, stimulate CD11c(-) type 2 dendritic cell precursors and CD11c(+) dendritic cells to produce type I IFN. J Immunol 2001, 166:2291-2295.
17. Bauer M, Redecke V, Ellwart JW, et al.: Bacterial CpG-DNA triggers activation and maturation of human CD11c(-), CD123(+) dendritic cells. J Immunol 2001, 166:5000-5007.
18. Hartmann E, Wollenberg B, Rothenfusser S, et al.: Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res 2003, 63:6478-6487.
19. Martin P, Del Hoyo GM, Anjuere F, et al.: Characterization of a new subpopulation of mouse CD8alpha+ B220+ dendritic cells endowed with type 1 interferon production capacity and tolerogenic potential. Blood 2002, 100:383-390.
20. Kuwana M, Kaburaki J, Wright TM, et al.: Induction of antigen-specific human CD4(+) T cell anergy by peripheral blood DC2 precursors. Eur J Immunol 2001, 31:2547-2557.
21. Pertl U, Luster AD, Varki NM, et al.: IFN-gamma-inducible protein-10 is essential for the generation of a protective tumor-specific CD8 T cell response induced by single-chain IL-12 gene therapy. J Immunol 2001, 166:6944-6951.
22. Tannenbaum CS, Tubbs R, Armstrong D, et al.: The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. J Immunol 1998, 161:927-932.
23. Strieter RM, Polverini PJ, Kunkel SL, et al.: The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem 1995, 270:27348-27357.
24. Kemp TJ, Elzey BD, Griffith TS: Plasmacytoid dendritic cell-derived IFN-alpha induces TNF-related apoptosis-inducing ligand/Apo-2L-mediated antitumor activity by human monocytes following CpG oligodeoxynucleotide stimulation. J Immunol 2003, 171:212-218.
25. Ballas ZK, Krieg AM, Warren T, et al.: Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J Immunol 2001, 167:4878-4886.
26. Vollmer J, Weeranta R, Payette P, et al.: Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol 2004, 34:251-262.
27. Marshall JD, Fearon K, Abbate C, et al.: Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions. J Leukoc Biol 2003, 73:781-792.
28. Hartmann G, Battiany J, Poeck H, et al.: Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells. Eur J Immunol 2003, 33:1633-1641.
29. Davis HL: Use of CpG DNA for enhancing specific immune responses. Curr Top Microbiol Immunol 2000, 247:171-183.
30. Hemmi H, Kaisho T, Takeda K, Akira S: The roles of Toll-like receptor 9, MyD88, and DNA-dependent protein kinase catalytic subunit in the effects of two distinct CpG DNAs on dendritic cell subsets. J Immunol 2003, 170:3059-3064.
31. Baines J, Celis E: Immune-mediated tumor regression induced by CpG-containing oligodeoxynucleotides. Clin Cancer Res 2003, 9:2693-2700.
32. Heckelsmiller K, Rall K, Beck S, et al.: Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model. J Immunol 2002, 169:3892-3899.
33. Kawarada Y, Ganss R, Garbi N, et al.: Nk- and cd8(+) T cell-mediated eradication of established tumors by peritumoral injection of cpg-containing oligodeoxynucleotides. J Immunol 2001, 167:5247-5253.
34. Lonsdorf AS, Kuekrek H, Stern BV, et al.: Intratumor CpG-oligodeoxynucleotide injection induces protective antitumor T cell immunity. J Immunol 2003, 171:3941-3946.
35. Blazar BR, Krieg AM, Taylor PA: Synthetic unmethylated cytosine-phosphate-guanosine oligodeoxynucleotides are potent stimulators of antileukemia responses in naive and bone marrow transplant recipients. Blood 2001, 98:1217-1225.
36. Carpentier AF, Chen L, Maltonti F, Delattre JY: Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice. Cancer Res 1999, 59:5429-5432.
37. Decker T, Schneller F, Sparwasser T, et al.: Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. Blood 2000, 95:999-1006.
38. Jahrsdorfer B, Hartmann G, Racila E, et al.: CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens. J Leukoc Biol 2001, 69:81-88.
39. Decker T, Hipp S, Kreitman RJ, et al.: Sensitization of B-cell chronic lymphocytic leukemia cells to recombinant immunotoxin by immunostimulatory phosphorothioate oligodeoxynucleotides. Blood 2002, 99:1320-1326.
40. Cho HJ, Takabayashi K, Cheng PM, et al.: Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism. Nat Biotechnol 2000, 18:509-514.
41. Tighe H, Takabayashi K, Schwartz D, et al.: Conjugation of protein to immunostimulatory DNA results in a rapid, long-lasting and potent induction of cell-mediated and humoral immunity. Eur J Immunol 2000, 30:1939-1947.
42. Yi AK, Hornbeck P, Lafrenz DE, Krieg AM: CpG DNA rescue of murine B lymphoma cells from anti-IgM-induced growth arrest and programmed cell death is associated with increased expression of c-myc and bcl-xL. J Immunol 1996, 157:4918-4925.
43. Yi AK, Chang M, Peckham DW, et al.: CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry. J Immunol 1998, 160:5898-5906.
44. Lipford GB, Bauer M, Blank C, et al.: CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. Eur J Immunol 1997, 27:2340-2344.
45. Roman M, Martin-Orozco E, Goodman JS, et al.: Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med 1997, 3:849-854.
46. Vabulas RM, Pircher H, Lipford GB, et al.: CpG-DNA activates in vivo T cell epitope presenting dendritic cells to trigger protective antiviral cytotoxic T cell responses. J Immunol 2000, 164:2372-2378.
47. Wild J, Grusby MJ, Schirmbeck R, Reimann J: Priming MHC-I-restricted cytotoxic T lymphocyte responses to exogenous hepatitis B surface antigen is CD4+ T cell dependent. J Immunol 1999, 163:1880-1887.
48. Chu RS, Targoni OS, Krieg AM, et al.: CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med 1997, 186:1623-1631.
49. Kim SK, Ragupathi G, Musselli C, et al.: Comparison of the effect of different immunological adjuvants on the antibody and T-cell response to immunization with MUC1-KLH and GD3-KLH conjugate cancer vaccines. Vaccine 1999, 18:597-603.
50. Schwarz K, Storni T, Manolova V, et al.: Role of Toll-like receptors in costimulating cytotoxic T cell responses. Eur J Immunol 2003, 33:1465-1470.
51. Zwaveling S, Mota SC, Nouta J, et al.: Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol 2002, 169:350-358.
52. Miconnet I, Koenig S, Speiser D, et al.: CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide. J Immunol 2002, 168:1212-1218.
53. Kim SK, Ragupathi G, Cappello S, et al.: Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates. Vaccine 2000, 19:530-537.
54. Liu HM, Newbrough SE, Bhatia SK, et al.: Immunostimulatory CpG oligodeoxynucleotides enhance the immune response to vaccine strategies involving granulocyte-macrophage colony-stimulating factor. Blood 1998, 92:3730-3736.
55. Sandler AD, Chihara H, Kobayashi G, et al.: CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma. Cancer Res 2003, 63:394-399.
56. Heckelsmiller K, Beck S, Rall K, et al.: Combined dendritic cell- and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy. Eur J Immunol 2002, 32:3235-3245.
57. Stern BV, Boehm BO, Tary-Lehmann M: Vaccination with tumor peptide in CpG adjuvant protects via IFN-gamma-dependent CD4 cell immunity. J Immunol 2002, 168:6099-6105.
58. Kim TY, Myoung HJ, Kim JH, et al.: Both E7 and CpG-oligodeoxynucleotide are required for protective immunity against challenge with human papillomavirus 16 (E6/E7) immortalized tumor cells: involvement of CD4+ and CD8+ T cells in protection. Cancer Res 2002, 62:7234-7240.
59. Davila E, Celis E: Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity. J Immunol 2000, 165:539-547.
60. Warren TL, Bhatia SK, Acosta AM, et al.: APC stimulated by CpG oligodeoxynucleotide enhance activation of MHC class I-restricted T cells. J Immunol 2000, 165:6244-6251.
61. Wooldridge JE, Ballas Z, Krieg AM, Weiner GJ: Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood 1997, 89:2994-2998.
62. Warren TL, Dahle CE, Weiner GJ: CpG oligodeoxynucleotides enhance monoclonal antibody therapy of a murine lymphoma. Clin Lymphoma 2000, 1:57-61.
63. Vicari AP, Chiodoni C, Vaure C, et al.: Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J Exp Med 2002, 196:541-549.
64. Davila E, Kennedy R, Celis E: Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade. Cancer Res 2003, 63:3281-3288.
65. Egeter O, Mocikat R, Ghoreschi K, et al.: Eradication of disseminated lymphomas with CpG-DNA activated T helper type 1 cells from nontransgenic mice. Cancer Res 2000, 60:1515-1520.
66. Weigel BJ, Rodeberg DA, Krieg AM, Blazar BR: CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma. Clin Cancer Res 2003, 9:3105-3114.
67. Carpentier AF, Auf G, Delattre JY: CpG-oligonucleotides for cancer immunotherapy: review of the literature and potential applications in malignant glioma. Front Biosci 2003, 8:115-127.
68. Jones TR, Obaldia N III, Gramzinski RA, et al.: Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys. Vaccine 1999, 17:3065-3071.
69. Davis HL, Suparto II, Weeratna RR, et al.: CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans. Vaccine 2000, 18:1920-1924.
70. Krieg AM: CpG motifs: the active ingredient in bacterial extracts? Nat Med 2003, 9:831-835.
71. Halperin SA, Van Nest G, Smith B, et al.: A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine 2003, 21:2461-2467.